Products and Pipeline
Housey Pharma focuses upon the creation and discovery of new prescription and non-prescription medicines to treat rapidly and uniformly fatal human diseases, as well as for certain chronic diseases for which current therapies are inadequate to achieve a complete cure or durable long-term remission. We also develop advanced drug creation and discovery technologies, an area in which our company's scientists have a proven track record.
Technology Licensing Programs
Areas of Application
Patent Status
Countries With Issued or Pending Patents
Development Stage
Commercially Licensed and Marketed
Cell‐Based Assay Technologies Invented at Housey Pharma
Early
Late
Cell‐Based Lead Optimization
Drug Discovery for All Diseases
ISSUED
> 20
Modulators of Drug‐Resistant Mutants (Theramuteins) in All Forms of Cancer.
Drug Discovery In Oncology
ISSUED
> 20
Inlicensed/Outlicensed Technology
Early
Late
Drug‐Resistant Bcr‐Abl Mutants
CML and certain other Leukemias
ISSUED
> 10
Prescription Track
Therapeutic Compounds
Indication(s)
Clinical Development Phase
Commercially Marketed
Diabetes
Pre‐Clinical
Phase 1
Phase 2
Phase 3
HP‐211 (Botanical IRS‐2 Activator)
Type 2 Diabetes
HP‐508 (Beta Cell Regeneration)
Type 1 Diabetes
HP‐233 (Small Molecule IRS‐2 Activator)
Type 2 Diabetes
HP‐038 (Small Molecule IRS‐2 Activator)
Type 2 Diabetes
Obesity and Steatosis
Pre‐Clinical
Phase 1
Phase 2
Phase 3
Novel Hormonal Target
Obesity, NASH, and Steatosis
Oncology
Pre‐Clinical
Phase 1
Phase 2
Phase 3
HP‐2 and HP‐3 Series Inhibitors for Selected Protein Kinase Targets
Drug‐Resistant Cancers
Products Available
Without a Prescription
Indication(s)
Development Phase
Commercially Marketed
Pre‐Clinical
Clinical
Axulin® (tablet formulation)
First approval in Canada1
1Approved on May 1, 2014. Health Canada has classified Axulin® as a Natural Health Product and has assigned to it Natural Product Number (NPN) # 80050544.
Nutritional Support for Diabetes, Metabolic Syndrome, Polycystic Ovarian Syndrome (PCOS) Pre‐Diabetes
Canada
U.S.
Future Commercial Approvals
Pending in:
Mexico
Targeted in 2024:
Selected countries in the European Union
